Surgery for lung cancer after chemo or targeted therapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether combining chemo or targeted therapy before surgery can help people with non-small cell lung cancer that may require removing a whole lung. We want to see if this approach makes the surgery safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of lung cancer called non-small cell lung cancer, which is at a stage that might be removed with surgery (stages T2–4 N0–2).
- Your surgeon believes you may need to have an entire lung removed (pneumonectomy).
- You must have received chemo or targeted therapy before surgery (neoadjuvant therapy).
- Your heart, lungs, liver, and kidneys must work well enough for major surgery.
- You cannot have had prior chest surgery or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This study tests whether doing surgery only after checking if the tumor shrinks with chemo-immunotherapy is safe and effective for people with locally advanced lung cancer. It may help avoid surgery if the cancer hasn't responded well.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This study looks at whether doing surgery after immunotherapy (with or without chemo) can be less invasive than originally planned. If your lung cancer shrunk enough after treatment that you might need a smaller surgery than first thought, this trial could help find the best approach.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.